European Neuromodulation Professionals Join Americans at INS Meeting in Barcelona
About 1500 neuromodulation professionals from all over the world assembled in Barcelona, Spain earlier this month for the 15th World Congress of the International Neuromodulation Society. The scientific program was preceded by an “Innovations in Neuromodulation” session dealing with commercialization issues. The full-day session, chaired from UI Chicago and Marc Russo from the Hunter Pain Clinic in…
Overcoming Drug Addiction
Since the early days of the neurotechnology industry, a major challenge confronting vendors and researchers has been overcoming obstacles presented . Though much progress has been made, there is still a bias among many clinicians, regulators, payers, and patient advocacy groups who see drugs as the only viable therapy, and regard neurotech devices as a last resort, if at all. As NBR senior consulti…
Neuromodulation Makes Gains in Psychiatric Disorders
The market for treating psychiatric disorders with neuromodulation therapy continues to progress as vendors report progress and investigators share new research findings. We reported last month on the formation of Inner Cosmos, which is developing a subcutaneous stimulation system for treating depression [NBR Apr22 p1]. Earlier this month, Neuronetics, the first neuromodulation firm to gain FDA cle…
Entrepreneurs and Executives Present at 2021 Bioelectronic Medicine Forum
About 85 professionals from the bioelectronic medicine industry participated in the 2021 Bioelectronic Medicine Forum, held online earlier this month. The fourth annual event will return to New York City in 2022. Keynote speaker at this year’s event was Murthy Simhambhatla, CEO of SetPoint Medical. He started ’s definition of bioelectronic medicine: “Stimulating nerves and tapping into the body’s i…
Neurotech Reports Plans Commercialization Workshop for July 28
Neurotech Reports, the publisher of this newsletter, announced that the third annual Neurotech Commercialization Workshop will take place on July 28, 2022. The one-day event, which was held on-line only in 2020 and 2021, will take place in New York City in 2022, in conjunction with the Neuroergonimcs/NYC Neuromodulation conference, although there will be an option for on-line participation. The wor…
Bioelectronic medicine investors discuss outlook in NYC
Venture capital professionals helping to build the bioelectronic medicine industry shared their insights on the investments climate at the 2022 Bioelectronic Medicine Forum held in New York City earlier this month. A panel discussion with three venture capital professionals active in the space brought out some valuable insights for startups established firms alike. The session was moderated Jennifer French.
Over Promise and Therapeutic Delivery
Readers of this publication have been exposed to a number of new and promising forms of neuromodulation that exploit novel anatomical targets or unique stimulation paradigms. As we report on page 1 of this issue, several new neuromodulation approaches for treating pain have emerged recently, including subwave neuromodulation, chemogenetic neuromodulation, and HD-SCS. While previous generations of new SCS paradigms have demonstrated clinical, if not financial success, these newest approaches have yet to be proven.
BCI Industry Witnesses New Deals and Competitors
The market for brain-computer interface systems has expanded considerably in recent months as new vendors have entered the space and existing players have moved to solidify their positions. Investor interest remains strong despite—or perhaps because of—tech entrepreneurs’ investment in companies like Blackrock Neurotech, Kernel, and Neuralink [NBR Jul21 p1]. One new entrant in the BCI space is a Po…
BioElectRx Business Report
Contents Dry eye device therapies staged for a comeback Olympic Ophthalmics and Oyster Point are pursuing neuromodulation therapies despite Allergan’s device exit. Closed-loop VNS for heart failure has untapped potential Startup firm Ceryx Medical is using respiratory sinus arrhthmia as a key input in their system. New indications loom large for bioelectronic medicine Two industry veterans and an NIH representative offered advice on finding new opportunities.
Lower-Extremity FES System Exploits Dual Stimulation
One of the first commercial applications of functional electrical stimulation was foot drop stimulation, to address gait abnormalities caused post stroke or other neurological disorders. Several neurorehabilitation firms in Canada, Europe, and the U.S. emerged offering either surface or minimally invasive neurostimulation devices. Recently, a team of clinicians and neural engineers in Washington state developed a new approach to foot-drop stimulation.